Conditions: Gastroesophageal Reflux Disease
Keywords: Gastroesophageal reflux disease
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 517
Healthy volunteers: no

Brief summary:
The purpose of this study is to assess the efficacy and safety of rabeprazole 10mg once and twice daily in maintenance therapy for PPI resistant gastroesophageal reflux disease patients.

Detailed description:
This is randomized, multicenter, parallel-group, double-blind trial that investigates the efficacy and safety of rabeprazole 10mg twice daily over a period of 52 weeks. The 8-week Treatment Period (unblinded) was followed by a 52-week Maintenance Period (blinded). Participants with cure (modified Los Angeles Classification Grade N or Grade M) at the final endoscopy of the Treatment Period were entered into the Maintenance Period. Participants without cure were discontinued from the study. The participants in the Treatment Period were randomized to take Arm C or Arm D at a ratio of 1:1. The non-recurrence rate as endoscopically confirmed at 52 weeks shall be the primary end point, and this shall be examined through a randomized, multicenter, parallel-group, double-blind trial that investigates the efficacy and safety of rabeprazole 10mg twice daily over a period of 52 weeks.

Arms:
arm 1: None arm 2: None arm 3: None arm 4: None

Interventions: intervention 1: Rabeprazole intervention 2: Rabeprazole intervention 3: Rabeprazole intervention 4: Rabeprazole
Intervention descriptions: intervention 1: Rabeprazole 10 mg was administered orally twice daily during the treatment period for 8 weeks (unblinded). intervention 2: Rabeprazole 20 mg was administered orally twice daily during the treatment period for 8 weeks (unblinded). intervention 3: Rabeprazole 10 mg or 20 mg were administered orally twice daily during the treatment period (unblinded), and 10 mg was administered once daily during the maintenance period (double-blind). intervention 4: Rabeprazole 10 or 20 mg were administered orally twice daily during the treatment period (unblinded), and 10 mg was administered twice daily during the maintenance period (double-blind).

Protocol document: